Enterprise Europe Network

New active principles for drugs useful in the treatment of inflammatory diseases, type 2 diabetes mellitus, hypercholesterolemia, dyslipidemias and atherosclerosis

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20190311001
Published
11/03/2019
Last update
18/03/2019
Expiration date
18/03/2020

Keywords

Partner keyword: 
Organic Chemistry
Clinical Research, Trials
Pharmaceutical Products / Drugs
Pharmaceuticals/fine chemicals
Manufacture of basic pharmaceutical products
Research and experimental development on biotechnology
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish university has developed new drugs which reduce glucose and cholesterol levels with less toxicity compared to other similar compounds. This lower toxicity could imply the development of a more effective and tolerable treatment for these conditions. There are no natural derivative compounds with benzopyran structure on the market that regulates these metabolic alterations. Researchers are looking for license or technical cooperation agreements and/or financial agreements with investors.

Description

Description: 

In the field of chemistry and pharmacology, different researchers have tried to develop treatments consisting of peroxisome proliferator-activated receptors agonists (PPARα and PPARγ), involved in the regulation of lipids, carbohydrates and inflammation, making them therapeutic targets for the treatment of type 2 diabetes, metabolic syndrome, obesity, hyperlipidemias, cardiovascular diseases (atherosclerosis) and neurodegenerative diseases.
These compounds, in particular, the synthetic thiazolidinediones, have proved to be effective for treating some of these conditions, however, some of them failed due to their associated toxicity. Similarly, dual PPARα/PPARγ agonists such as saroglitazar are under surveillance. As a result, the treatment of the affected population is mainly carried out through a cocktail of different drugs such as statins, with their associated adverse effects, and hypoglycemic drugs.
This invention is the solution to toxicity problems of the others PPAR α/γ agonists keeping treatment effectiveness. New compounds, Polycerasoidol and Polycerasoidin derivatives, have been developed to reduce glucose and cholesterol levels.
The main application sector of these compounds would be the pharmaceutical sector, as they can be active principles of drugs for the treatment of type 2 diabetes mellitus, dyslipidemias, metabolic syndrome and associated complications such as cardiovascular, inflammatory diseases. It is a great market due to the percentage of the population affected by these metabolic disorders has increased mainly due to new lifestyle habits (sedentary lifestyle and increased consumption of processed foods).
Researchers are seeking companies to reach license agreements. Technical cooperation with companies or research centers will be considered too, in order to make further progress in drug development. Finally, researchers are seeking investors interested in developing new drugs to carry out clinical trials through financial agreements.

Advantages & innovations

Cooperation plus value: 
The most innovative aspect of this invention is that allows solving the toxicity problems of the others PPAR α/γ agonists keeping the treatment effectiveness. The main advantages provided by the invention are: - Lower toxicity of these compounds compared to other PPAR agonists. - Greater effectiveness against existing treatments such as cocktails of statins and hypoglycemic drugs

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
- Type of partner sought: Enterprise, research centers or investors. - Specific area of activity of the partner: pharmaceutical activities, drug development, clinical trials. - Task to be performed: licensing the invention, testing the drug, carrying out clinical trials, production and marketing of the product. The Spanish university is looking for: • Pharma companies to reach license agreements • Pharma companies or research institutions to further co-development of the drug • Pharma companies or investors to carry out clinical trials

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500